Has Michael Orzo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,142 in general payments to Michael Orzo, MD across 424 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Orzo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Orzo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Orzo, MD

Interventional Pain Medicine · Dublin, OHNPI 1548225287

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 424 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Boston Scientific at 26.1% of the total.

$10,142in general payments, 2019–2025

Across 424 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$3K
AbbVie$2K
Si-bone, Inc.$671
Collegium Pharmaceutical, Inc.$584
Pfizer$548
Medtronic$546
plus $4K from 22 others

What the payments were for

Food & beverage$10,142100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	77	$2,650
AbbVie(2 entities)	113	$1,612
Si-bone, Inc.	8	$671
Collegium Pharmaceutical, Inc.	40	$584
Pfizer	42	$548
Medtronic(2 entities)	10	$546
Scilex Pharmaceuticals Inc.	23	$416
Vertos Medical, Inc.	9	$377
IBSA Pharma Inc.	23	$376
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	16	$308
Biotronik NRO, Inc.	6	$265
Biodelivery Sciences International, Inc.	17	$260
Nevro Corp.	4	$243
Abbott	4	$238
Stryker	4	$200
Vertex	2	$149
Saluda Medical Americas, Inc.	2	$123
Biohaven Pharmaceutical Holding Company Ltd.	4	$87
Nalu Medical, Inc.	2	$81
Curonix LLC	1	$81
Lundbeck LLC	4	$79
Almatica Pharma LLC	3	$71
SPR Therapeutics, Inc	4	$64
Biohaven Pharmaceuticals, Inc.	2	$51
Tersera Therapeutics LLC	1	$20
Pacira Pharmaceuticals Incorporated	1	$19
Fidia Pharma USA Inc.	1	$15
Relievant Medsystems, Inc.	1	$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,142 in reported general payments places this provider in the 65th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio →

Medicare billing

Part B allowed, 2024

$74,845

Medicare patients

Services billed

2,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fentanyl	17	$1,158
Gabapentin	64	$972
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	34	$848
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	31	$723
Tizanidine Hcl	46	$400
Morphine Sulfate ErMorphine Sulfate	12	$186
Oxycodone Hcl	12	$166
Cyclobenzaprine Hcl	11	$159
Methylprednisolone	20	$106

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Dublin

Kristen BamberDublin$11K
Kyle SmithDublin$5K
Tim ChowdhuryDublin$2K
Krishna DeshpandeDublin$1K
Gladstone McDowellColumbus$660K
Humam AkbikFairfield$116K
Sara NashiCincinnati$116K
Jaudat MahmoodKent$97K
Omar AliSpringfield$67K
Dustin ReynoldsWesterville$61K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →